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Introduction
Germline mutations in STK11/LKB1 (Hemminki et al., 1998) 
are associated with Peutz–Jeghers syndrome (Jeghers et al., 
1949), an autosomal-dominant disease characterized by gastro-
intestinal hamartomatous polyps and hyperpigmentation of the 
oral mucosa. Patients with Peutz–Jeghers syndrome have en-
hanced susceptibility to many cancers (Olschwang et al., 2001; 
Lim et al., 2003; Hearle et al., 2006). Somatic mutations that re-
sult in the inactivation of LKB1 are also found in sporadic can-
cers such as lung adenocarcinoma (Sanchez-Cespedes et al., 
2002; Ji et al., 2007), cervical carcinoma (Wingo et al., 2009), 
pancreatic cancer (Su et al., 1999), and melanoma (Guldberg 
et al., 1999; Rowan et al., 1999).
Several lines of evidence support a critical role of LKB1 
as a tumor suppressor (Sanchez-Cespedes et al., 2002; McCarthy 
et al., 2009; Miyoshi et al., 2009), but work in murine models, 
in particular, has shown a prominent role of LKB1 in suppressing 
metastasis. For example, Kras expression rapidly cooper-
ates with inactivation of several other tumor suppressor genes 
(e.g., p53 and p16/INK4a) to promote locally aggressive mela-
noma or nonsmall cell lung cancer, but only Lkb1-deficient tu-
mors exhibit widespread hematogenous and lymphatic metastasis 
(Ji et al., 2007; Carretero et al., 2010; Liu et al., 2012). In both 
models, Lkb1 inactivation is associated with increased expres-
sion of CD24, expansion of tumor-initiating fractions, and acti-
vation of Src family kinases, but the direct mechanism whereby 
LKB1 loss facilitates metastasis is poorly understood. This in-
creased propensity of Lkb1-deficient tumors for advanced local 
growth and early metastatic spread has been supported by re-
cent human studies (Wingo et al., 2009; Kline et al., 2011; Liu 
et al., 2013).
LKB1 is a highly conserved serine/threonine kinase that 
phosphorylates a consensus motif found in 14 different kinases 
(Lizcano et al., 2004). LKB1 function is most intimately tied to 
AMP-activated protein kinase (AMPK), a central regulator of 
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To investigate this, we depleted LKB1 in the human melanoma 
cell line A2058 (BRAFV600E/PTEN null/RB1 null) and the mu-
rine melanoma cell line GR285 (KrasG12D/p53 null/p16 null; 
Fig. 1 A; Monahan et al., 2010) and tested their ability to form 
invadopodia on the fluorescent gelatin matrix (Fig. 1 B). Surpris-
ingly, we found no difference in the percentage of cells forming 
invadopodia in either melanoma cell line with LKB1 depletion 
(Fig. 1 C).
We considered the possibility that subtle differences might 
be missed in this fixed time point assay. To test this more rigor-
ously, we performed live-cell time-lapse microscopy of the well-
characterized human melanoma cell line WM-266-4 expressing 
an actin marker Lifeact-GFP plated on Alexa Fluor 568–gelatin 
over a period of 27 h (Video 1). We then developed an unbiased 
automated vision approach to classify “degraders” and “nonde-
graders” from multiple imaging fields (Berginski et al., 2014). 
As expected, the percentage of cells with invadopodia increased 
as a function of time (Fig. 1 D). However, similar to our results 
obtained from fixed time points, we observed no significant dif-
ferences in the percentage of cells forming invadopodia with or 
without LKB1.
As an additional approach, we used lentiviral/retroviral 
reconstitution of KrasG12D/Lkb1-null melanoma cells established 
from a recently described autochthonous murine model of met-
astatic melanoma (Fig. S1 A; Liu et al., 2012). We confirmed 
that reexpression of LKB1 (addback) promoted phosphoryla-
tion of AMPK and its downstream effector acetyl-CoA carbox-
ylase in three LKB1-deficient cell lines (LKB498, LKB878, 
and TKL2; Fig. S1 B). We co-cultured these LKB1-null and re-
constituted melanoma cells with WM-266-4 cells (as a positive 
control) on fluorescent gelatin (Fig. 1 E). We observed robust 
matrix-degrading invadopodia in WM-266-4 cells but surpris-
ingly found no invadopodia in LKB498-null or addback cells or 
in the two other LKB1-deficient melanoma cell lines (LKB878 
and TKL2) derived from the same genetic model (unpublished 
data). Together, these data indicate that the enhanced invasion 
and metastasis resulting from the loss of LKB1 likely do not 
rely on differences in invadopodia formation but instead reflect 
a different property of the cells.
LKB1 limits single-cell and  
collective migration
The finding that LKB1 does not appear to influence the propor-
tion of cells forming invadopodia prompted us to more closely 
examine its effects on cell migration. We first assessed random 
single-cell motility in 3D collagen and found that LKB1 add-
back reduced cell speed by a modest 30% (Fig. 2 A). To test the 
effect of LKB1 addback on 3D migration in a collective con-
text, we generated tumor cell spheroids and examined invasion 
into 3D collagen gels (Fig. 2 B). At all concentrations tested, we 
found reduced invasive outgrowth in cells with LKB1 addback 
and a further reduction as compared with null cells at higher 
collagen concentrations (Fig. 2 C). We next investigated motil-
ity on 2D surfaces. One prominent characteristic of mesenchy-
mal cells is their ability to migrate on ECM substratum in a 
biphasic fashion, with optimal cell speed at intermediate matrix 
concentrations (Goodman et al., 1989; DiMilla et al., 1993). 
cellular metabolism under conditions of energy stress (Shaw 
et al., 2004b). However, it is becoming increasingly clear that 
LKB1 has many AMPK-independent functions in morphogene-
sis (Rodríguez-Fraticelli et al., 2012) and cancer (Lo et al., 2012; 
Nguyen et al., 2013). In addition to AMPK, LKB1 activates the 
brain-specific kinases (BRSKs; BRSK1 and BRSK2), microtu-
bule affinity-regulating kinases (MARKs; MARK1, MARK2, 
MARK3, and MARK4), salt-inducible kinases (SIKs; SIK1, SIK2, 
and SIK3), and nua (novel)/SNF1-like kinases (NUAK1 and 
NUAK2), which participate in multiple cellular functions, such 
as anoikis, actomyosin contractility, and cell polarity (Marcus 
and Zhou, 2010). For instance, in neurons, LKB1 not only pro-
motes axon specification through BRSKs (Barnes et al., 2007; 
Shelly et al., 2007) but also controls axon branching via NUAK1 
(Courchet et al., 2013).
Genetic studies in Caenorhabditis elegans (Watts et al., 
2000) and Drosophila melanogaster (Martin and St Johnston, 
2003) first identified a key role of LKB1 in the establishment of 
cell polarity, which has since been extended to mammalian sys-
tems (Baas et al., 2004). This is most evident in epithelial cells 
in which LKB1 activity is required to maintain apical–basal 
polarity in the intestine (Baas et al., 2004), pancreas (Hezel 
et al., 2008), and mammary gland (Partanen et al., 2012). 
Loss of apical–basal polarity is thought to be a quintessential 
characteristic of epithelial-derived cancer, which occurs during 
epithelial–mesenchymal transition (Chaffer and Weinberg, 2011). 
However, murine tumor models with LKB1 loss show loss of 
apical–basal polarity in some but not all (Contreras et al., 2008; 
Lo et al., 2012) cancers, suggesting that LKB1 has context-
dependent functions.
LKB1 is also found in more motile mesenchymal cells, 
which typically display a front–rear polarity that spontaneously 
allows cells to migrate (Ridley et al., 2003). Cells must estab-
lish this asymmetry during directed migration toward soluble 
growth factor (chemotaxis), surface-bound ECM (haptotaxis), 
and mechanical cues (durotaxis; Petrie et al., 2009). Guiding 
principles have emerged to describe how directional migration 
is orchestrated, which include actin polymerization, stabiliza-
tion of adhesions, focalized proteolysis, cell contractility, and 
detachment (Friedl and Alexander, 2011). Furthermore, signifi-
cant technological advances have enabled more rigorous inves-
tigation of directional cell migration (Shamloo et al., 2008; Wu 
et al., 2012). Despite recent progress, how LKB1 participates in 
regulating directional cell migration remains incompletely un-
derstood. Based on the finding that loss of LKB1 promotes me-
tastasis in several tumor types, here, we seek to interrogate the 
cell biological basis by which LKB1 controls migration and 
invasion in melanoma.
Results
Loss of LKB1 does not affect invadopodia 
formation in melanoma cells
Given the potent effect of LKB1 loss on invasion and metasta-
sis, we expected that LKB1 loss would promote the formation 
of invadopodia, the matrix-degrading organelles often formed 
by metastatic cancer cells (Chen, 1989; Yamaguchi et al., 2005). 
301Loss of LKB1 disrupts haptotaxis • Chan et al.
Figure 1. Loss of LKB1 does not affect invadopodia formation in melanoma cells. (A) Western blot showing lentiviral shRNA knockdown of a nontar-
geting sequence (NS) or LKB1 (knockdown [KD]) in human A2058 (BRAFV600E/RB null) and mouse GR285 (KrasG12D/p53 null/p16 null) melanoma. 
(B) Invadopodia formation on Alexa Fluor 647–gelatin. GFP is a marker of knockdown, and cells were stained with Alexa Fluor 568–phalloidin to label 
actin. (C) Percentage of cells with invadopodia shown as means ± SEM. (A2058: nontargeting sequence, n = 297; KD#1, n = 413; KD#2, n = 300. 
GR285: nontargeting sequence, n = 321; KD#1, n = 255; KD#2, n = 312.) (D) Live-cell invadopodia assay shows no difference in invadopodia formation 
over time. Dashed lines show raw data and solid lines are best-fit curves to the data. (Trial #1: nontargeting sequence, n = 60; LKB1 knockdown, n = 60. 
Trial #2: nontargeting sequence, n = 82, LKB1 knockdown, n = 101.) (E) Invadopodia assay on Alexa Fluor 405–gelatin of WM-266-4 (BRAFV600D/PTEN 
null) Lifeact (LA)-GFP cells and tdTomato-labeled LKB498 (KrasG12D/Lkb1 null) or LKB1 addback melanoma. Cells were stained with Alexa Fluor 647–phalloidin 
to label actin. Insets show magnified region of invadopodia. Bars, 20 µm.
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Figure 2. LKB1 limits single-cell and collective cell migration in melanoma. (A) Single-cell speed of LKB498 cells in 1 mg/ml 3D collagen. (null, n = 73; 
addback, n = 83.) (B) Spheroid invasion of LKB498 cells into 3.2 mg/ml 3D collagen. Cells were stained with Alexa Fluor 568–phalloidin to label 
actin and Hoechst 33342 to label nuclei. (C) Spheroid outgrowth of LKB498 cells into increasing concentrations of 3D collagen. (1 mg/ml: null, n = 22; add-
back, n = 24. 2 mg/ml: null, n = 21; addback, n = 27. 4 mg/ml: null, n = 30; addback, n = 29. 6 mg/ml: null, n = 20; addback, n = 23. 8 mg/ml: 
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At all matrix concentrations tested, LKB1 addback reduced 
single-cell migration speed (Fig. 2 D). However, regardless of 
LKB1 status, cells displayed biphasic motility with optimal mi-
gration occurring on 1 µg/ml fibronectin. This suggests that, de-
spite the reduction in cell speed observed upon reintroduction 
of LKB1, cells with or without LKB1 can still respond similarly 
to absolute differences in ECM concentration.
To assay collective cell migration in 2D, we performed 
scratch wound assays of cell monolayers, and by time-lapse mi-
croscopy, we used a method to automatically detect the collective 
cell margin and quantify wound closure over time. Consistent 
with previous work (Carretero et al., 2010; Liu et al., 2012), we 
observed delayed closure upon reintroduction of LKB1 com-
pared with the null cells (Fig. 2 E). Upon careful examination of 
the time-lapse videos (Video 2 and Video 3), we noticed that 
cells with LKB1 addback paused for over an hour and lined up 
parallel to the wound edge (Fig. 2 F). In contrast, LKB1-null 
cells completely ignored this boundary and migrated directly 
into the cleared area without delay. During the generation of a 
scratch wound, the underlying ECM is often removed, and we 
speculated that LKB1 addback cells were aligning with this dis-
continuous ECM. To test this notion, we performed a scratch 
wound on an LKB1 addback monolayer plated on fluorescent 
fibronectin and observed a strong tendency for LKB1 addback 
cells to align with the ECM boundary (Fig. 2 G). These data 
highlight the ability of LKB1 to limit cell migration both in 
single-cell and collective contexts and imply that the loss of 
LKB1 impairs ECM boundary sensing.
LKB1 is necessary for haptotaxis but is 
not required for chemotaxis to PDGF
Based on the observation that migrating cells with LKB1 dis-
played a “pausing” at the wound boundary, we postulated that 
cells with LKB1 could recognize ECM content on the surface 
but that LKB1-null cells were refractory to this cue. To test this 
hypothesis, we used microfluidic chamber devices in which we 
previously demonstrated an ability to generate stable linear gra-
dients of immobilized ECM (Fig. 3 A; Wu et al., 2012). This 
approach allows visualization of directional cell migration to-
ward ECM (haptotaxis) for time periods of ≤24 h. We mixed 
tdTomato-labeled LKB1-null cells and GFP-labeled addback 
cells and observed their haptotactic migration by time-lapse 
microscopy in the chamber. We quantified three independent 
parameters to describe overall migration behavior: velocity; the 
forward migration index (FMI; Monypenny et al., 2009), the 
distance migrated in the direction of the gradient over the total 
accumulated distance; and persistence, the displacement over 
the total path length. We considered haptotaxing cells as those 
with a mean FMI and a 95% confidence interval >0. Cells that 
did not haptotax had a mean FMI and a 95% confidence interval 
encompassing 0. To our surprise, we found that cells with in-
tact LKB1 (addback) migrated directionally toward the gradi-
ent, whereas cells without LKB1 had no directional preference 
(Fig. 3 B). We confirmed this observation in LKB878 LKB1-
null/addback cells (Fig. S2 A) as well as in TKL2 cells (Fig. S2 B), 
which had a significantly enhanced ability to haptotax upon 
LKB1 addback. Furthermore, to determine whether the loss of 
LKB1 could abolish haptotactic capacity in other mesenchymal 
cells, we depleted LKB1 in IA32 mouse embryonic fibroblasts 
(Fig. S2 C; Cai et al., 2008). Similar to our results using mela-
noma cells, fibroblasts depleted of LKB1 failed to haptotax in 
contrast to their control counterparts (Fig. S2, D and E).
To test whether proximal integrin signaling was still intact, 
we held LKB1-null and addback melanoma cells in suspension 
for 3 h and subsequently plated them for 1 h on fibronectin-
coated surfaces (Fig. 3 C). Loss of integrin engagement resulted 
in reduced phosphorylation of FAK at tyrosine 397, which was 
restored in cells in both null and addback cells upon adhesion. 
Together, these data indicate that the loss of LKB1 does not 
affect the recognition of absolute concentrations of ECM but 
ablates the ability to distinguish a gradient of ECM across a 
single cell.
To confirm our findings in a 3D migration environment, 
we used microfluidics chambers to generate a 3D ECM gradi-
ent. To accomplish this, we seeded cells in 3D collagen gels 
and established a linear gradient of fibronectin within the col-
lagen gel by diffusion (Fig. 3 D). By confocal microscopy, we 
observed that the Cy5-fibronectin became associated with col-
lagen fibrils in a concentration gradient from one side of the 
chamber to the other. Once this immobilized gradient formed, 
we flushed the soluble Cy5-fibronectin out of the source channel 
and observed a stable gradient, confirming that this fibronectin 
was bound to the collagen in the gel. In this configuration, we 
observed a similar difference in haptotactic capacity between 
LKB1-null and addback cells as in 2D, whereby the null cells 
were unable to sense and/or respond to the fibronectin gradient 
(Fig. 3 E). These results further support the notion that loss of 
LKB1 abolishes directional migration toward ECM gradients.
One possible explanation for this difference in haptotactic 
migration is that the presence or absence of LKB1 affects a 
nonautonomous property of the cells. For example, LKB1 loss 
could promote enhanced secretion of matrix metalloproteinases 
(MMPs; Ou et al., 2012). MMPs could ostensibly cause the 
degradation of matrix surrounding the cell, rendering it unable 
to sense an ECM gradient. Because all of the 2D and 3D hapto-
taxis experiments described in this paper used populations of 
LKB1-null and addback cells mixed together in the same cham-
ber (with differential fluorescent marking), we do not think that 
a nonautonomous effect is a likely explanation for the differ-
ence. However, to test whether invasion into 3D collagen was 
null, n = 28; addback, n = 23.) (D) Single-cell speed of LKB498 cells on increasing fibronectin concentrations. (0.1 µg/ml: null, n = 94; addback, 
n = 104. 1 µg/ml: null, n = 99; addback, n = 96. 10 µg/ml: null, n = 149; addback, n = 162. 100 µg/ml: null, n = 134; addback, n = 150.) 
(E) Montage images and edge outlines of time-lapse scratch wounds. (F) Relative wound area over time. (LKB498: null, n = 43; addback, n = 32. TKL2: null, 
n = 33; addback, n = 33.) Gray shaded area indicates times at which relative wound area shows significant differences with P < 0.01. Insets show magni-
fied plots of time points at which pausing occurs (represented by the bars) at the wound boundary. (G) Scratch wound of LKB498 LKB1 addback monolayer on 
Cy3-fibronectin (FN). DIC, differential interference contrast. All data are shown as means ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 
by two-tailed unpaired t test. Bars, 100 µm.
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Figure 3. LKB1 is necessary for haptotaxis but is not required for directional migration to PDGF. (A) Schematic of mixed fluorescent cells in microfluidics 
chamber system. (B) LKB1 is required for haptotaxis of LKB498 cells to fibronectin. (null, n = 99; addback, n = 75.) (C) Western blots showing phosphoryla-
tion of FAK in LKB498 cells upon suspension (Susp.) or adhesion (Adh.) to fibronectin. Add, addback. (D) Epifluorescence image of 3D haptotaxis chamber 
with Alexa Fluor 647–fibronectin (FN) gradient across 1 mg/ml 3D collagen. Inset shows a confocal image of fibronectin bound to collagen fibrils. (E) LKB1 
is necessary for haptotaxis of LKB498 cells in 3D collagen. (null, n = 132; addback, n = 89.) (F and G) Spheroid invasion of TKL2 cells into 3D collagen 
is cell autonomous. (null, n = 118; addback, n = 120.) Data are shown as a box and whisker plots with the boxes extending from the 25th through 75th 
percentiles with the lines in the middle as the medians. Whiskers range from the minimum to maximum values. **, P < 0.01 by two-tailed unpaired t test. 
(H) LKB1 is dispensable for chemotaxis of LKB498 cells to PDGF. (null, n = 34; addback, n = 39.) (I) Western blots showing phosphorylation of AKT upon 
acute stimulation with 200 ng/ml PDGF. All haptotaxis and chemotaxis data are shown as mean ± 95% confidence intervals. ***, P < 0.001 by two-tailed 
unpaired t test. Bars, 100 µm. v, velocity; D/T, displacement (D) over the total path length (T).
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cell autonomous, we examined spheroid invasion with mixed 
fluorescent LKB1-null and addback cells (Fig. 3 F). Despite the 
fact that the cells were in close contact for many hours, the ma-
jority of cells invaded cell autonomously with LKB1-null cells 
migrating a farther distance as compared with addback cells 
(Fig. 3 G). Moreover, to formally test whether MMP inhibition 
was able to restore haptotaxis in LKB1-null cells, we performed 
haptotaxis experiments in the presence of the MMP inhibitor 
GM6001, used at concentrations that were sufficient to block 
invadopodial matrix degradation in A2058 cells (Fig. S2 F), 
both in 2D (Fig. S2 G) and in 3D (Fig. S2 H) configurations. We 
found no deviation from our results obtained in the absence of 
MMP inhibition, demonstrating that the difference in haptotaxis 
between LKB1-null and addback cells is not MMP dependent.
Several studies have implicated the role of LKB1 in main-
taining cell polarity (Asada et al., 2007; Rodríguez-Fraticelli 
et al., 2012). Therefore, it is possible that loss of LKB1 impairs all 
forms of directional migration. To investigate this possibility, 
we used microfluidics chambers to generate a soluble gradient 
of PDGF, a potent chemotactic ligand for melanoma cells, and 
assessed directional migration toward this cue. Remarkably, re-
gardless of LKB1 status, cells efficiently chemotaxed to PDGF 
(Fig. 3 H). Consistent with this, LKB1 depletion in fibroblasts 
had no effect on chemotaxis to PDGF (unpublished data). We 
confirmed that downstream signaling of the PDGF receptor was 
intact in LKB1-null and addback melanoma cells by measuring 
AKT phosphorylation upon acute PDGF stimulation (Fig. 3 I). 
These data demonstrate that the loss of LKB1 specifically ab-
lates directional migration toward ECM gradients but not to-
ward soluble growth factor cues.
Membrane targeting and kinase activity  
are required for haptotaxis
LKB1 contains a highly conserved C terminus that is thought 
to play an integral role in its regulation (Fig. 4 A). In particular, 
LKB1 has a CAAX prenylation motif that mediates its mem-
brane association and an upstream PKA/p90RSK phosphorylation 
site that has been shown to regulate cell polarity (Martin and 
St Johnston, 2003; Barnes et al., 2007; Shelly et al., 2007). To de-
termine whether these posttranslational modifications contribute 
Figure 4. Membrane targeting and kinase activity of LKB1 are required for haptotaxis. (A) Sequence alignment of vertebrate LKB1 C terminus. Black 
shade indicates identical amino acids, and gray shade indicates similar amino acids. (B) Western blots of LKB1 reconstitution in LKB498 cells with wild type 
(WT) or prenylation (C430A), phosphorylation (S428A), and kinase-dead (K78I) mutants. Add, addback. (C) Membrane association and kinase activity 
are required for haptotaxis. (addback, n = 52; C430A, n = 37; S428A, n = 68; K78I, n = 42.) All data are shown as mean ± 95% confidence intervals. 
*, P < 0.05 by two-tailed unpaired t test. v, velocity; D/T, displacement (D) over the total path length (T).
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also tested the requirement of NUAK1 by shRNA knockdown 
and found no effect on haptotaxis (Fig. S3, D, E, and L). As an 
additional approach, we used the recently described selective 
inhibitor of NUAK family kinases WZ4003 (Banerjee et al., 2014). 
We confirmed that the NUAK inhibitor decreased myosin light 
chain phosphorylation at serine 19 in a dose-dependent manner 
(Fig. S3, F and G); however, similar to NUAK1 knockdown, 
LKB1 addback cells treated with the NUAK inhibitor could still 
haptotax (Fig. S3 H). Finally, we simultaneously depleted all 
isoforms of the SIK family kinases and found no effect on hap-
totaxis (Fig. S3, I–L). Collectively, these data indicate that the 
LKB1 effectors AMPK, BRSK, NUAK, and SIK are not required 
for haptotaxis (Figs. 5 A and S3 L).
The MARK family kinases (Drewes et al., 1997) are mam-
malian orthologues of the C. elegans Par-1 (Guo and Kemphues, 
1995), which play key roles in regulating cell polarity and 
are, therefore, attractive targets that may regulate directional 
migration (Sapir et al., 2008; Mejia-Gervacio et al., 2012). To 
determine whether MARK family kinases are necessary for 
haptotaxis, we depleted all the expressed isoforms (MARK2, 
MARK3, and MARK4) in LKB1 addback melanoma cells 
(Fig. S4, A and B). In contrast to the other LKB1 effectors, we 
found that MARK family kinases are essential for haptotaxis 
(Fig. 5 B).
We next asked whether MARK family kinase activity 
could regulate haptotactic migration. A primary function of 
the MARK family kinases is to phosphorylate the microtubule- 
associated proteins MAP4, MAP2, and Tau (Illenberger et al., 
1996). According to our RNA-Seq data, the predominant micro-
tubule-associated protein expressed in melanoma cells is MAP4. 
By Western blotting, we detected MAP4 (220 kD; Chapin 
et al., 1995) and phosphorylated MAP4 (121 kD), which was 
enhanced in addback as compared with null cells (Fig. 5 C). 
The recently described MARK inhibitor 39621 (half-maximal 
inhibitory concentration = 3.6 µM) is an ATP-competitive and 
highly selective MARK family kinase inhibitor that has mini-
mal effects on other AMPK-related kinases (Timm et al., 2011). 
We verified that the MARK inhibitor was functional by its abil-
ity to block MAP4 phosphorylation in both LKB1-null and ad-
dback cells (Fig. 5 C). To determine whether MARK activity 
is required for haptotaxis, we treated LKB1 addback cells with 
the MARK inhibitor. Consistent with our hypothesis, treatment 
with the MARK inhibitor abrogated haptotaxis (Fig. 5 D). We 
substantiated this observation using fibroblasts treated with the 
MARK inhibitor using a before and after a wash-in regimen in 
our microfluidic chambers (Fig. S4 C).
As a complementary approach to treatment with MARK 
inhibitor, we overexpressed a known MARK3-T211A/S215A mu-
tant that LKB1 and MARK kinase cannot phosphorylate/activate 
(Marx et al., 2010). We confirmed its function as a dominant- 
negative (DN; DN-MARK3) by its ability to completely abro-
gate endogenous MAP4 phosphorylation, which was even lower 
than we observed in LKB1-null cells (Fig. 5 E). Overexpression 
of DN-MARK3 in LKB1 addback cells abolished haptotaxis 
both in 2D (Fig. 5 F) and 3D (Fig. 5 G). Collectively, these data 
demonstrate that MARK family kinases are the major LKB1 
substrates that are required for haptotaxis.
to LKB1’s regulation of haptotaxis, we reconstituted LKB1-null 
melanoma cells with mutant forms of LKB1 that were resistant 
to modification. We introduced a C430A mutation, which abol-
ishes LKB1 prenylation and is predicted to prevent association 
with the plasma membrane (Collins et al., 2000). We also made 
a S428A mutation, which prevents cAMP and extracellular sig-
nal-related kinase–mediated PKA/p90RSK phosphorylation at 
this site (Sapkota et al., 2001). Additionally, to test whether ki-
nase activity was required, we reconstituted cells with a kinase-
dead mutant (K78I) of LKB1. We verified that all the LKB1 
mutants had equal levels of expression (Fig. 4 B). Interestingly, 
phosphorylation of S428 was increased in the prenylation- 
deficient C430A mutant, indicating a possible feedback between 
phosphorylation and membrane targeting. Both cells expres-
sing wild-type LKB1 or the S428A mutant displayed enhanced 
phosphorylation of AMPK. This corresponded with their ability 
to haptotax toward a fibronectin gradient (Fig. 4 C). Interest-
ingly, although we found that PKA/p90RSK phosphorylation 
was not required for haptotaxis per se, haptotactic fidelity was 
significantly diminished. Cells expressing the C430A or the 
K78I mutant showed impaired AMPK phosphorylation, and 
they could not haptotax. Our finding that AMPK phosphory-
lation was reduced with the C430A mutant is also consistent 
with data reported from the recent generation of a mutant LKB1 
knock-in mouse (Houde et al., 2014). Together, these results 
demonstrate that membrane association and kinase activity of 
LKB1 are required for haptotaxis.
MARK family kinases are the key LKB1 
substrates necessary for haptotaxis
The requirement for LKB1 kinase activity in governing hap-
totaxis prompted us to next ask which downstream substrate 
of LKB1 is necessary. LKB1 is a master regulatory kinase that 
phosphorylates 14 different kinases and activates all of them 
with the exception of maternal embryonic leucine zipper kinase 
(Lizcano et al., 2004). To determine which LKB1 substrates are 
expressed, we performed RNA-Seq (RNA sequencing) tran-
scriptome analysis of LKB498-null and addback cells. Of the 
known LKB1-activated kinase substrates, mRNA for nine of 
them was expressed: Ampk1, Brsk1, Nuak1, Sik1, Sik2, Sik3, 
Mark2, Mark3, and Mark4 (Fig. S3 A). Of note, we did not find 
dramatic transcriptional changes in any of these upon LKB1 
reintroduction (Table S1).
To test the importance of each LKB1 substrate in hapto-
taxis, we used lentiviral shRNA knockdown and pharmacologi-
cal inhibition. We first tested the requirement for AMPK, the 
major LKB1 substrate involved in cell metabolism that inhibits 
mammalian target of rapamycin (Shaw et al., 2004a) by using 
multiple lentiviral shRNAs to knock down AMPK (Fig. S3 B). 
Interestingly, we found that LKB1-mediated haptotaxis does 
not require AMPK (Fig. S3 L). In addition, lentiviral knock-
down of BRSK1, which plays a key role in neuronal polariza-
tion, demonstrated that it is dispensable for haptotaxis (Fig. S3, 
C and L; Barnes et al., 2007). Given that the nua kinase (NUAK) 
family kinases are known to inhibit the activity of myosin phos-
phatase to control cell adhesion and are a promising candidate 
to regulate directional cell migration (Zagórska et al., 2010), we 
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results in microtubule destabilization (Illenberger et al., 1996). 
Based on previous studies showing microtubule involvement 
in the regulation of cell polarity and directional migration 
(Magdalena et al., 2003; Xu et al., 2005), we hypothesized that 
Haptotaxis does not require MAP4  
or microtubules
MARK phosphorylation of MAP4 on KXGS repeats 1 and 4 
induces its dissociation from microtubules and subsequently 
Figure 5. MARK family kinase activity is necessary for haptotaxis. (A) Several LKB1 substrates are not required for haptotaxis. Substrates not expressed 
were not tested in haptotaxis experiments and are listed as not available (N/A). (B) MARK family kinases are required for haptotaxis in LKB498 cells. 
(addback, n = 125; addback + MARK2, 3, and 4 knockdown [KD], n = 106.) (C) Western blots showing MARK inhibitor (MARKinh) 39621 (20 µM) 
validation in LKB498 cells. Add, addback; IP, immunoprecipitation; IB, immunoblot. (D) MARK inhibitor blocks haptotaxis in LKB498 cells. (addback, n = 
133; MARK inhibitor, n = 92.) (E) Western blots validating effect of dominant-negative (DN) MARK3 overexpression in LKB498 cells. (F and G) DN-MARK3 
blocks haptotaxis of LKB498 cells in 2D (F) and 3D (G). (2D: addback, n = 130; DN-MARK3, n = 131. 3D: addback, n = 48; DN-MARK3, n = 40.) All 
data are shown as mean ± 95% confidence intervals. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by two-tailed unpaired t test. v, velocity; D/T, displace-
ment (D) over the total path length (T).
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Figure 6. Haptotaxis does not require MAP4 or microtubules. (A) Western blots showing overexpression of active MAP4 in LKB498 cells. exp., exposure. 
(B and C) Active MAP4 does not affect haptotaxis of LKB498 cells in 2D (B) and 3D (C). (addback, n = 51; GFP-MAP4-S914A/S1046A [SA], n = 48.) 
(D) Nocodazole depolymerizes microtubules in LKB498 cells. Bar, 20 µm. (E) Nocodazole (noc) treatment of LKB498 LKB1 addback cells has no effect on 
haptotaxis. (640 nM, n = 37; 10.24 µM, n = 35.) (F and G) Washing of nocodazole alone (F) does not block haptotaxis (before wash in, n = 69; wash 
in, n = 51) but together with MARK inhibitor (G) blocks haptotaxis in IA32 fibroblasts. (before wash in, n = 155; wash in, n = 107.) All haptotaxis data 
are shown as mean ± 95% confidence intervals. **, P < 0.01; ***, P < 0.001 by two-tailed unpaired t test. v, velocity; D/T, displacement (D) over the 
total path length (T).
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MARK phosphorylation of MAP4 would be the key mechanism 
upstream of microtubules to regulate haptotaxis. To test this, we 
generated a MAP4 mutant GFP-MAP4-S914A/S1046A, which 
prevents MARK family kinase phosphorylation of MAP4 and 
promotes microtubule assembly (Chinnakkannu et al., 2010). 
We overexpressed GFP-MAP4-S914A/S1046A in LKB1 add-
back cells (Fig. 6 A) and tested their ability to haptotax. Unex-
pectedly, overexpression of mutant MAP4 in LKB1 addback 
cells had no effect on haptotaxis in 2D (Fig. 6 B) and 3D (Fig. 6 C). 
This result suggests that MARK regulates haptotaxis in a man-
ner independent of its ability to affect microtubules through 
MAP4 phosphorylation.
We next investigated the role of microtubules in the pro-
cess of haptotaxis by perturbing microtubule dynamics upon 
treatment of cells with nocodazole. We determined that micro-
tubules were completely depolymerized at a nocodazole con-
centration of 640 nM (Fig. 6 D). We then evaluated the ability 
of LKB1 addback cells to haptotax in the presence of nocodazole 
at this concentration (Fig. 6 E). To our surprise, despite clear al-
teration in cellular morphology during migration, nocodazole 
had no discernable effect on haptotaxis. To further support this, 
we used a 16-fold higher dose and found the same result. Like-
wise, in fibroblasts, we performed nocodazole wash in and 
found no effect on their ability to haptotax (Fig. 6 F). However, 
in accordance with our previous finding, wash in of nocodazole 
together with MARK inhibitor blocked haptotaxis (Fig. 6 G). 
Collectively, these data highlight the striking finding that MARK 
regulates haptotaxis in a manner that does not depend on MAP4 
or intact microtubules.
MARK family kinases limit cell invasion
To determine whether the loss of haptotaxis as a result of the 
inhibition of MARK function also affects 3D invasion, we pre-
pared spheroids of LKB498 LKB1 addback cells overexpress-
ing DN-MARK3 and embedded them into collagen (Fig. S5 A). 
Overexpression of DN-MARK3 enhanced invasive outgrowth 
in cells with intact LKB1 (Fig. S5 B). Furthermore, treatment of 
LKB1 addback cells with the MARK inhibitor enhanced inva-
sion into 3D collagen (Fig. S5 C). To confirm this observation 
in another LKB1-deficient melanoma cell line derived from the 
same genetic model, we generated TKL2 cells depleted of en-
dogenous MARK3 and overexpressed DN-MARK3 (Fig. 7 A). 
Importantly, overexpression of DN-MARK3 had no effect on 
AMPK phosphorylation (Fig. 7 B). Similar to our observation 
in LKB498 cells, MARK disruption in TKL2 cells enhanced 
spheroid invasion into 3D collagen (Fig. 7, C and D). These find-
ings indicate that MARK family kinases, substrates of LKB1 
that are required for haptotaxis, limit melanoma invasion.
Discussion
In this work, we discovered a hitherto undescribed role for an 
LKB1-MARK axis as a mediator of directional migration to-
ward gradients of ECM. Therefore, we postulate that ECM cues 
limit cell invasion in LKB1-competent cells. In Ras-driven mel-
anoma, the loss of LKB1 signaling through MARK and loss of 
the ability to recognize ECM gradients is associated with enhanced 
invasion. Future studies should investigate whether this applies 
to metastasis in vivo.
We anticipated that LKB1 loss would facilitate matrix 
degradation through invadopodia formation to promote invasion. 
To our surprise, multiple highly metastatic melanoma cell lines 
did not form invadopodia, regardless of LKB1 status. This does 
not exclude the possibility that invadopodia can facilitate cell 
invasion and metastasis; however, our data highlight the loss of 
haptotaxis as an alternative explanation for how the loss of LKB1 
facilitates invasion in melanoma. Many tumors in vivo display a 
“capsule” of collagen surrounding the tumor periphery, which is 
thought to result from the outward pushing of preexisting colla-
gen bundles as the tumor proliferates but does not invade this 
ECM barrier (Hompland et al., 2008). We speculate that the loss 
of the ability to haptotax caused by LKB1 loss confers a greater 
degree of plasticity between modes of migration and a failure to 
respect natural tumor boundaries. Although cells with intact 
LKB1 can sense and respect ECM boundaries, cells without 
LKB1 are free to wander and invade even in the absence of clas-
sic invadopodia.
Figure 7. MARK inhibition facilitates cell invasion. (A) Western blot of 
overexpression of DN-MARK3 in TKL2 cells shows no effect on AMPK phos-
phorylation. pACC, phosphorylated acetyl-CoA carboxylase. (B) Quan-
tification of Western blot data (n = 3) in A is shown as means ± SEM. 
**, P < 0.01; ***, P < 0.001 by two-tailed unpaired t test. (C) DN-
MARK3 enhances spheroid invasion into 4 mg/ml 3D collagen. Cells 
were stained with Alexa Fluor 568–phalloidin to label actin. Bar, 100 µm. 
(D) Quantification of data in C is shown as means ± SEM. (day 0–3: null, 
n = 14; addback, n = 9; addback + DN-MARK3, n = 22.) **, P < 0.01; 
***, P < 0.001 by one-way analysis of variance (ANOVA) by Dunnett’s 
post-test, as compared with addback.
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CD24+ subpopulation (Liu et al., 2012), Src family kinase regu-
lation (Carretero et al., 2010; Liu et al., 2012), cellular metabo-
lism via AMPK (Shaw et al., 2004b), and resistance to anoikis 
(Cheng et al., 2009). Our data suggest a new mechanism by 
which LKB1 may limit tumor progression, directly related to 
invasion and metastasis: loss of LKB1 leads to loss of respon-
siveness to inhibitory ECM cues.
We found that MARK was the predominant substrate of 
LKB1 required for haptotaxis. This is intriguing in light of previ-
ous data showing the requirement for both LKB1 and MARK in 
establishing asymmetry in C. elegans (Kemphues et al., 1988). 
How does MARK confer the ability of cells to undergo hapto-
taxis? We initially thought that MARK would designate polarity 
through microtubule regulation by phosphorylating/inactivating 
MAP4. However, we provide substantial evidence to support the 
idea that the ability of cells to haptotax is independent of MAP4 
and microtubule regulation. It is possible that MARK regulates 
the actin cytoskeleton by phosphorylating and inhibiting guanine 
nucleotide exchange factor–H1, a guanine nucleotide exchange 
factor for RhoA (Yamahashi et al., 2011). Alternatively, a recent 
genetic screen for kinases that repress the Hippo–Yes-associated 
protein (YAP) pathway in human cells identified LKB1 and 
MARK as critical regulators upstream of YAP (Mohseni et al., 
2014). Indeed, emerging evidence has established a link between 
the Hippo–YAP pathway and control of the actin cytoskeleton 
(Lucas et al., 2013). A more recent study suggests that MARK 
phosphorylates and localizes the scaffolding protein DIXDC1 to 
focal adhesions to suppress metastasis in lung cancer (Goodwin 
et al., 2014). Collectively, these findings highlight an increas-
ingly apparent connection between an ancient, highly conserved 
polarity pathway and cancer progression.
In summary, we provide substantial evidence that the loss 
of LKB1 results in the loss of directional migration toward 
ECM cues. Our data also support the intriguing hypothesis 
that the loss of haptotaxis as a result of LKB1 loss facilitates 
invasion. Future studies will investigate how MARK, the key 




The following commercial antibodies were obtained: rabbit anti-LKB1 
(D60C5), rabbit anti–phospho-LKB1 (Ser428; C67A3), rabbit anti–AMPK-
 (D5A2), rabbit anti–phospho-AMPK- (Thr172; 40H9), rabbit anti-BRSK1 
(D10F2), rabbit anti-NUAK1/ARK5, rabbit anti-MARK2, rabbit anti-MARK3, 
rabbit anti-MARK4, and rabbit anti-SIK2 (D28G3; Cell Signaling Technol-
ogy); rabbit anti-SIK3 (Abgent); mouse anti-GFP (Takara Bio Inc.); rabbit 
anti–phospho-MAP4 (Ser941; Abnova); rabbit anti-MAP4 (EMD Millipore); 
and mouse anti-GAPDH (6C5; Life Technologies). Fibronectin was ob-
tained from BD. Alexa Fluor 568–phalloidin, Alexa Fluor 647–phalloidin, 
and Hoechst 33342 were obtained from Life Technologies. Rat tail colla-
gen type I, PDGF-BB, MARK/Par-1 activity inhibitor 39621, and GM6001 
MMP inhibitor were purchased from EMD Millipore.
Cell culture and viral transduction
A2058 (BRAFV600E/RB null) and WM-266-4 (BRAFV600D/PTEN null) 
human melanoma cell lines were purchased from ATCC. The GR285 
(KrasG12D/p53 null/p16 null) murine melanoma cell line was derived from 
4-hydroxy-tamoxifen (4-OHT)–treated Tyr-Cre-ERT2/KrasLSL-G12D/+/p53L/L/p16L/L  
mice (Monahan et al., 2010). The Tyr-Cre-ERT2 allele is a 4-OHT–inducible 
Cre recombinase-estrogen receptor fusion transgene under the control 
The processes of tumor cell invasion and, ultimately, metas-
tasis are dependent on the ability of cells to migrate. In multiple 
contexts, cells that lacked LKB1 still displayed robust front-
rear polarity and migrated faster than cells with intact LKB1; 
however, cells without LKB1 could not haptotax. We previously 
demonstrated that the Arp2/3 complex and the formation of 
lamellipodia are necessary for haptotaxis but not chemotaxis to 
PDGF (Wu et al., 2012). Likewise, cells without LKB1 were 
unhindered in their ability to chemotax to PDGF, indicating that 
the loss of haptotaxis is a specific effect in response to ECM 
cues and does not reflect a general failure of directional migra-
tion. Based on these findings, it is tempting to speculate that an 
LKB1-dependent signaling network is necessary to spatially or-
ganize Arp2/3-based lamellipodial protrusions in order for cells 
to respond to ECM cues. It will be interesting to examine how 
protrusions are differentially spatially and temporally organized 
in cells with and without LKB1.
An important open question about LKB1 and its role in 
cellular signaling is how it is regulated. Studies have suggested 
that PKA phosphorylation of LKB1 is required for proper neu-
ronal polarization (Barnes et al., 2007; Shelly et al., 2007). 
However, the recent generation of an LKB1 knock-in mouse 
that was resistant to phosphorylation at this site showed no overt 
neurological phenotype, suggesting that there may be context-
dependent effects (Houde et al., 2014). In light of these data, we 
found that cells expressing LKB1-S428A could still haptotax, 
albeit with less fidelity, suggesting that this phosphorylation site 
plays a more subtle role in this LKB1 function. On the other 
hand, membrane targeting and LKB1 kinase activity were strictly 
required for haptotaxis. Our observation that the LKB1 prenyl-
ation mutant was hyperphosphorylated at S428 suggests that the 
inability to associate with the membrane causes LKB1 to be 
more susceptible to phosphorylation. It is also possible that 
phosphorylation facilitates LKB1 membrane association, which 
could be necessary for optimal haptotactic sensing. Investiga-
tion of the interplay between integrin engagement, LKB1 mem-
brane targeting, and dynamic phosphorylation at the PKA/p90RSK 
site is an area of active ongoing research.
Interaction with the ECM is critical for many, if not most 
phases, of tumor progression. One hallmark of metastatic dis-
semination is resistance to apoptosis (Hanahan and Weinberg, 
2000). Previously, a kinome-wide loss-of-function screen iden-
tified SIK1 as a regulator of p53-dependent anoikis, a specific 
type of apoptosis caused by loss of integrin-mediated adhesion 
(Cheng et al., 2009). SIK1 was also necessary for LKB1 to sup-
press anchorage-independent growth. In the same vein as the 
loss of SIK1 activity in conferring anoikis resistance, our data 
demonstrate a connection between the loss of LKB1 and MARK 
activity and the loss of haptotaxis to facilitate melanoma inva-
sion. Moreover, cells with or without LKB1 displayed biphasic 
motility and enhanced FAK phosphorylation upon integrin- 
mediated adhesion, suggesting that proximal integrin signaling is 
still intact. Together with the functional haptotaxis experiments, 
these data support the notion that LKB1 can translate integrin 
signaling into a polarized cell response across a gradient. It is likely 
that LKB1 plays multiple roles in limiting tumor progression 
in vivo using a variety of mechanisms, such as the expansion of a 
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LKB1-C430A, LKB1-S428A, MARK3-T211A/S215A (DN-MARK3), and 
GFP-MAP4-S914A/S1046A (GFP-MAP4-SA) mutants were generated by 
overlap extension PCR and verified by sequencing.
Western blotting
Cells were lysed in radioimmunoprecipitation assay buffer (50 mM Tris, 
pH 8.0, 1% NP-40, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% 
SDS, protease inhibitors, and phosphatase inhibitor cocktail [PhosSTOP; 
Roche]). Lysates (10–20 µg total protein) were run on 10% SDS-PAGE 
gels and transferred to polyvinylidene fluoride membrane (Immobilon-P; 
EMD Millipore). Membranes were probed with specific antibodies and 
HRP-conjugated secondary antibodies (Jackson ImmunoResearch Labora-
tories, Inc.). Western blots were developed with SuperSignal West Pico or 
Femto Chemiluminescent Substrate (Thermo Fisher Scientific), scanned on a 
ChemiDoc MP System (Bio-Rad Laboratories), and quantified using Image 
Lab 5.0 software.
Invadopodia assay
Alexa Fluor 405–, Alexa Fluor 568–, and Alexa Fluor 647–gelatin were 
prepared using the corresponding protein-labeling kits (Life Technologies). 
Gelatin-coated coverslips were prepared as previously described (Artym 
et al., 2006). In brief, acid-washed coverslips were coated with 100 µg/ml 
poly-l-lysine in PBS for 20 min, washed in PBS, and subsequently incubated 
with 0.5% glutaraldehyde for 15 min. Coverslips were then washed, 
inverted onto an 80-µl drop containing an 8:1 mix of unlabeled 2 mg/ml 
gelatin/fluorescently labeled gelatin, and allowed to incubate for 10 min. 
Coverslips were quenched with 5 mg/ml sodium borohydride for 15 min 
and washed extensively before cell culture.
Live-cell invadopodia assay
Glass-bottomed dishes (MatTek Corporation) were coated with Alexa Fluor 
568–gelatin. Cells were plated 8–12 h before imaging at 37°C and 5% 
CO2 on an incubator fluorescent microscope (VivaView FL; Olympus) 
equipped with a 20× U Plan S Apochromat objective (NA 0.75 and work-
ing distance of 0.6 mm) with a motorized magnification changer set to 1× 
and a camera (Orca ER-AG c4742-80-12AG; Hamamatsu Photonics). 
Images of the fluorescent ECM and Lifeact-GFP–expressing cells (acquired 
every 30 min for 27 h) were first flat field corrected. Lifeact-GFP cells were 
identified by thresholding and connected component labeling. Fluorescent 
ECM images were photobleach corrected. Only the regions not under-
neath the cells were used to determine the appropriate photobleach correc-
tions to ensure that ECM degradation was not mistaken for photobleaching. 
Cells were tracked through the entire experiment, and the change in ECM 
fluorescence underneath each cell was measured between each image. An 
empirical threshold for between image fluorescence change was selected 
to identify cells that degraded the matrix.
Single-cell tracking
Glass-bottomed culture dishes were coated with fibronectin 37°C for 1 h. 
Coated dishes were then blocked with 5% BSA at 37°C for 1 h to prevent 
nonspecific cell adhesion. Cells were plated on fibronectin-coated dishes 
for 8–12 h before imaging. Time-lapse microscopy was performed on an 
incubator fluorescent microscope (VivaView FL) at 37°C and 5% CO2 
using a 20× objective with a motorized magnification changer set to 0.5×. 
Cell speed was measured with ImageJ using the Manual Tracking plugin 
(National Institutes of Health).
Wound-healing assay
Glass-bottomed culture dishes were coated with 10 µg/ml fibronectin and 
thoroughly washed. 106 cells were plated for 8–12 h before generating a 
scratch wound with a sterile P200 pipette tip. Images were acquired every 
10 min for 12 h on an incubator microscope (VivaView FL) at 37°C and 
5% CO2 using a 20× objective with a motorized magnification changer set 
to 0.5×. Wound edge detection at every time point was performed with 
ImageJ using methods as described by K. Straatman (Advanced Imaging 
Facilities, University of Leicester, Leicester, UK).
In brief, wound edges were first detected using the ImageJ function 
Process → Find Edges, sharpened, and thresholded. The Find Edges func-
tion was used again, and the lookup table for the resulting image was 
inverted. Next, the Analyze Particles function was applied with a lower 
bound set to 10,000 (background). Relative wound closure was quantified 
from measurements at every time point relative to the initial time point.
Immunofluorescent cell staining
For immunofluorescent staining, the cells were fixed, stained, and mounted 
as described previously (Bear et al., 2002). Cells were fixed with 4% 
of the melanocyte-specific tyrosinase promoter (Bosenberg et al., 2006). 
The Lox-STOP-Lox-KrasG12D allele harbors a G12D mutation in exon 2 of 
the endogenous murine Kras gene and contains a STOP cassette flanked 
by loxP sites that silences the expression of the mutant allele (Jackson et al., 
2001). Cre-mediated recombination removes this cassette and allows 
transcription from the mutated allele. The p16L allele was generated by 
inserting loxP sites 3.5 kb 5 to exon 1 and 3 to the p16INK4a exon 1, 
which is excised upon Cre expression and results in a null allele (Monahan 
et al., 2010). The p53L allele was generated by inserting loxP sites into 
Trp53 introns 1 and 10 and has been described previously (Jonkers et al., 
2001). Expression of Cre results in a null allele through the deletion 
of exons 2–10. LKB498, LKB878, and TKL2 (KrasG12D/Lkb1 null) mu-
rine melanoma cell lines were derived from 4-OHT–treated Tyr-Cre-ERT2/ 
KrasLSL-G12D/+/Lkb1L/L mice (Liu et al., 2012). The Lkb1L allele contains loxP 
sites flanking exons 2–6, which are deleted upon Cre-mediated recom-
bination to generate a null allele (Bardeesy et al., 2002). Murine em-
bryonic fibroblasts were described previously (Cai et al., 2008). All cell 
lines were cultured in DMEM, 10% FBS, 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 292 µg/ml l-glutamine. 293FT cells used for viral 
packaging were purchased from Life Technologies and transfected using 
X-tremeGENE 9 (Roche). The shRNAs targeting human and mouse LKB1 in 
Fig. 1 were designed and cloned into the HpaI–XhoI sites of pLL5.0(GFP) 
using methods as described previously (Cai et al., 2007). The 19-nt target 
sequence for human LKB1 for KD#1 is 5-GGGAAGGCTCTTACGGCAA-
3 and KD#2 is 5-GAAGAAGGAAATTCAACTG-3. The target sequence 
for mouse Lkb1 KD#1 is 5-GCCAAGCTCATCGGCAAGT-3 and KD#2 
is 5-GAGAAGCAGAAGATGTATG-3. The target sequence for the non-
targeting shRNA is 5-GATCGACTTACGACGTTAT-3, which has no exact 
match in the human, mouse, or rat genome, and has been described previ-
ously (Cai et al., 2007). Bulk populations of cells were transduced with 
lentivirus prepared from these constructs according to standard methods 
(Cai et al., 2007). GFP-positive cells were sorted by FACS and subjected 
to invadopodia assays 4–7 d after transduction.
V5-tagged mouse LKB1 was cloned into the multicloning site of the 
pLL5.5 lentiviral vector, which contains an internal ribosome entry site–GFP 
sequence, or following a GFP/tdTomato-T2A sequence to allow bicistronic 
expression of GFP/tdTomato and V5-LKB1. To generate LKB1 addback sta-
ble melanoma cell lines, bulk populations of LKB498/LKB878/TKL2-null cells 
were transduced with lentivirus prepared from these constructs and sorted 
for either GFP or tdTomato expression by FACS. Retroviral transduction of 
LKB1 into bulk populations was performed according to standard methods, 
and cells were selected for using 2–3 µg/ml puromycin for ≥2–3 d.
The pLKO.1-puro empty vector control and all other shRNAs for 
mouse Lkb1, Prkaa1 (Ampk1), Nuak1, Brsk1, Sik1, Sik2, Sik3, Mark2, 
Mark3, and Mark4 were purchased from the University of North Carolina 
Lenti-shRNA Core Facility, which uses the GE Healthcare TRC1 shRNA librar-
ies. For single shRNA experiments, bulk populations of cells were trans-
duced with lentivirus and selected with puromycin for 2–3 d. Cell lysates 
were then subjected to Western blotting to assess knockdown efficiency, 
and cells were assayed for directional migration 4–7 d after transduc-
tion. pLKO.1-hygro (24150) and pLKO.3G (14748; GFP marker) plasmids 
were purchased from Addgene and used for multiple knockdown experi-
ments. For experiments with knockdown using two shRNAs against the 
same mRNA to achieve a greater level of knockdown (Lkb1 and Nuak1), 
cells were simultaneously infected with lentivirus from pLKO.1-puro with 
one shRNA hairpin and a pLKO.1-hygro second shRNA hairpin. Cells were 
then selected with puromycin and 100 µg/ml hygromycin for 4–6 d and 
tested in directional migration assays 7–10 d after transduction. For triple 
shRNA knockdowns (Sik and Mark), LKB498 tdTomato-2A-V5-LKB1 cells 
were simultaneously infected with three lentiviruses with a single shRNA 
hairpin against each isoform cloned into pLKO.1-puro, pLKO.1-hygro, and 
pLKO.3G. Cells were selected with puromycin and hygromycin for 6–10 d 
(longer selection because of lower transduction efficiency), sorted for tdTo-
mato (addback) and GFP (third isoform knockdown) expression by FACS, 
and tested in haptotaxis assays 10–14 d after transduction. In Fig. 7, to 
generate TKL2 addback cells depleted of endogenous MARK3 and overex-
pressing DN-MARK3, bulk populations of TKL2 pBabe.puro-LKB1 stable ad-
dback cells were simultaneously transduced with pBabe.hygro-DN-MARK3 
and pLKO.3G-MARK3sh#06, which targets mouse but not human MARK3. 
Cells were selected with hygromycin for 4–6 d, and GFP-positive cells were 
sorted by FACS. A human MARK3 cDNA clone was obtained from the Uni-
versity of North Carolina Tissue Culture Facility, which uses the Human Vidal 
Orfeome 5.1. The mouse Map4 Mammalian Gene Collection clone was 
purchased from Life Technologies. LKB1-K78I was PCR amplified from pBabe.
puro-LKB1-K78I and subcloned into pLL5.0-GFP/tdTomato-2A-V5-LKB1. 
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culture chamber using a gel-loading pipette tip. The exit ports of the sink 
and source channels were connected to waste using tubing of an inner di-
ameter of 0.015 inches. 100-µl glass syringes (model 1710 TLL 100 µl 
SYR; Gastight; Hamilton) were connected to 27.5-gauge needles connected 
to the tubing. The source syringe and tubing were filled with serum-free 
DMEM containing the indicated chemoattractant and 10 µg/ml TRITC-dex-
tran to visualize the gradient. The sink syringe and tubing were filled with 
serum-free DMEM. The tubing was then inserted into the source and sink 
channels, respectively, and the syringe pump was operated at a flow rate 
of 20 nl/min. A stable gradient was then established in the cell culture 
chamber within 30 min and typically remained stable for 18 h as moni-
tored by TRITC-dextran fluorescent intensity.
Haptotaxis gradients
Identical chambers as in the chemotaxis experiments were prepared. After 
bonding device to dish, gradients were formed by diffusion via the ad-
dition of 400 µg/ml Cy5-fibronectin to the source channel followed by 
washing with sterile PBS. The gradient was visualized by epifluorescence 
imaging and performing a line scan before seeding cells in the culture 
chamber. Additionally, a before and after wash-in protocol was developed 
in which the PDMS devices were plasma cleaned for 1 min and not dried 
at 70°C to allow removal of the PDMS after forming the fibronectin gra-
dient. Cells were observed during haptotaxis for a minimum of 7 h, at 
which time the drug was added and the same cells were observed for an 
additional 8–12 h. This allowed matched drug versus nondrug treatment 
to confirm that any effects of the drugs on haptotaxis are not caused by 
chamber-to-chamber variability. For 3D haptotaxis assays, cells were first 
seeded in 1 mg/ml acid-neutralized collagen, after which the fibronectin 
gradient was formed.
Directional migration image acquisition and analysis
Chemotaxis and 3D haptotaxis assays were performed on a micro-
scope (Disk Scanning Unit; Olympus) with a 20× objective using Meta-
Morph imaging software (Molecular Devices). Images were collected 
every 10 min for >12 h. Haptotaxis assays on 2D were performed on 
a microscope (VivaView FL) using a 20× objective with a motorized 
magnification changer set to 0.5× and at the same time interval. Indi-
vidual cells were manually tracked using ImageJ software Manual 
Tracking plugin. Cells in 3D were tracked in x–y as in 2D assays. The 
tracks obtained were further analyzed using the chemotaxis tool devel-
oped by ibidi (Chemotaxis and Migration Tool). This analysis tool was 
used to extract the FMI, persistence, and velocity of cell tracks from the 
manual tracking results. Data were analyzed using Prism (GraphPad 
Software) and displayed as mean ± 95% confidence intervals. Statistical 
analysis for these parameters was subsequently performed using a two- 
tailed t test.
Online supplemental material
Fig. S1 depicts the strategy for reconstitution of LKB1-deficient melanoma 
cell lines. Fig. S2 shows that LKB1 is required for haptotaxis in multiple 
cell lines. Fig. S3 summarizes the results of evaluating the role of LKB1 
substrates in haptotaxis. Fig. S4 shows that MARK family kinases are 
required for haptotaxis. Fig. S5 reveals that a DN form of MARK en-
hances melanoma invasion into 3D collagen. Video 1 shows a live-cell 
invadopodia assay of WM-266-4 cells expressing Lifeact-GFP. Video 2 
shows a LKB1-null melanoma cell migration in a wound-healing assay. 
Video 3 shows LKB1 addback melanoma cell migration in a wound-heal-
ing assay. Table S1 lists the results from RNA-Seq analysis of LKB1-null 
and addback melanoma cells and is provided online as an Excel (Mi-
crosoft) file. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.201404067/DC1.
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paraformaldehyde and permeabilized in 0.1% Triton X-100 in PBS for 
10 min at room temperature. Cells were then blocked for 30 min in PBS 
containing 5% normal goat serum and 5% fatty acid–free BSA. Primary an-
tibodies were applied to cells in PBS containing 1% BSA overnight at 4°C. 
After washing the cells three times in PBS, fluorescent dye–conjugated sec-
ondary antibodies were diluted to 1:500 in 1% BSA in PBS and applied 
to the coverslips for 1 h. After three washes in PBS, the coverslips were 
mounted onto slides with Fluoromount-G (Electron Microscopy Sciences). 
Images were captured using a scanning confocal inverted microscope 
(FluoView FV1000; Olympus) equipped with a 40 or 100× U Plan Fluor 
N objective (NA 1.30). Maximum intensity projections were generated 
using FluoView software (Olympus).
Hanging droplet spheroids and spheroid collagen invasion
Hanging droplet spheroids were generated according to modified meth-
ods of those previously described (Timmins and Nielsen, 2007). Cells were 
trypsinized and resuspended in media at 0.5–1 × 105 cells/ml. 20 µl cell 
suspension was placed into each well of a 60-well minitray (Nunc; Thermo 
Fisher Scientific). The minitray was inverted and placed into a local humidi-
fication chamber. The humidification chamber was prepared by placing a 
60-mm tissue culture dish (with lid removed) filled with 8 ml PBS inside a 
150-mm tissue culture dish. Cells were incubated at 37°C 5% CO2 for 4 d 
to allow spheroid formation at the medium–air interface. For collagen inva-
sion assays, spheroids were embedded into collagen in 24-well tissue culture 
plates and followed for invasion for 3 d. Collagen type I, high concentra-
tion (8–11 mg/ml) was purchased from BD. For confocal microscopy of 
spheroid invasion, cells were simultaneously fixed/permeabilized in 4% 
paraformaldehyde and 0.1% Triton X-100 for 1 h. Cells were stained with 
fluorescent dye–conjugated phalloidin and Hoechst 33342 before visual-
izing on a microscope (FV1000) with a C Plan Fluor N objective (NA 0.3 
and working distance of 9 mm; 10XRC; Olympus).
RNA preparation, RNA-Seq, and quantitative RT-PCR (qRT-PCR)
Total RNA was isolated from cells with an RNeasy Plus Mini kit (QIAGEN) and 
validated to have RNA integrity numbers >8.5 using a 2100 Bioanalyzer 
(Agilent Technologies). For RNA-Seq, poly(A)+ RNA was enriched using the 
purification kit (Oligotex mRNA Mini Kit; QIAGEN) and fragmented with 
RNA fragmentation reagents (Ambion; Life Technologies). cDNA was syn-
thesized with reverse transcriptase (SuperScript II; Life Technologies) by ran-
dom priming followed by second-strand synthesis with DNA Polymerase I 
(Enzymatics) and purified using a PCR purification kit (QIAquick; QIAGEN). 
Libraries were prepared according to the manufacturer’s specifications 
(Illumina). Sequencing was performed using 50-bp single-end reads (HiSeq 
2000; Illumina). Reads were aligned to the reference mouse genome (mm9) 
using TopHat (Trapnell et al., 2009), and gene expression was estimated 
by calculating reads per kilobase per million reads (Mortazavi et al., 2008) 
for all Ensembl genes, analyzing only exonic reads. For qRT-PCR, cDNA 
was generated from total RNA (SuperScript II) using a 50:50% mixture 
of random primers (Invitrogen) and the Oligo(dT) primer (Promega). This 
cDNA was used directly with TaqMan Gene Expression Master Mix and 
TaqMan Gene Expression Assays (Applied Biosystems) to be read on a 
qRT-PCR machine (ViiA 7; Applied Biosystems). Sik1 and Gapdh TaqMan 
probes were obtained from Life Technologies. qRT-PCR data were analyzed 
by the Pfaffl method (Pfaffl, 2001).
Microfluidic device preparation
Transparency masks were printed using a high-resolution printer (Fineline 
Imaging). The pattern for the chamber was fabricated on 4-inch silicon 
wafers using a two-step photolithography process. The first step involved 
a 5-µm-tall layer of SU-8 (25) purchased from Microposit, and the micro-
capillaries were transferred to the wafer. After developing the first layer, 
a second 100-µm-tall layer of SU-8 (100) was applied to the same wafer, 
and after alignment, the channels were transferred to the wafer. After de-
veloping and postbaking, the silicon wafer was exposed to silane over-
night. Polymethylsiloxane (PDMS) was then poured on the wafer and cured 
overnight at 70°C. Individual PDMS devices were cut out from the wafer 
and placed in a clean dish until use. Ports were punched out in the devices. 
The devices were then washed with water and ethanol, blow dried, and 
plasma cleaned. The PDMS device was placed into contact with the glass-
bottomed dish immediately, ensuring that an irreversible seal was formed. 
The cell chamber ports were plugged with short pieces of tubing (0.0025 × 
0.03125 inch; Upchurch Scientific).
Chemotactic gradients
The cell culture chamber was filled with 10 µg/ml fibronectin for 1 h at 
37°C followed by flushing with sterile PBS. Cells were loaded into the cell 
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